LivaNova (LIVN) Competitors

$70.00 -1.67 (-2.33%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$69.83 -0.17 (-0.24%)

As of 05/15/2026 07:57 PM Eastern

LIVN vs. SNN, SOLV, PEN, GKOS, and BLCO

Should you buy LivaNova stock or one of its competitors? MarketBeat compares LivaNova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LivaNova include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Glaukos (GKOS), and Bausch + Lomb (BLCO). These companies are all part of the "medical equipment" industry.

How does LivaNova compare to Smith & Nephew SNATS?

LivaNova (NASDAQ:LIVN) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

LivaNova has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

In the previous week, LivaNova had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 4 mentions for LivaNova and 0 mentions for Smith & Nephew SNATS. LivaNova's average media sentiment score of 1.25 beat Smith & Nephew SNATS's score of 0.34 indicating that LivaNova is being referred to more favorably in the media.

Company	Overall Sentiment
LivaNova	Positive
Smith & Nephew SNATS	Neutral

97.6% of LivaNova shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

LivaNova has a net margin of 7.48% compared to Smith & Nephew SNATS's net margin of 0.00%. LivaNova's return on equity of 16.48% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Smith & Nephew SNATS	N/A	N/A	N/A

LivaNova presently has a consensus price target of $77.22, suggesting a potential upside of 10.32%. Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential upside of 4.64%. Given LivaNova's stronger consensus rating and higher possible upside, equities analysts clearly believe LivaNova is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40

Smith & Nephew SNATS has higher revenue and earnings than LivaNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.77	-$242.47M	$1.95	35.90
Smith & Nephew SNATS	$6.16B	2.05	$625M	N/A	N/A

Summary

LivaNova beats Smith & Nephew SNATS on 11 of the 15 factors compared between the two stocks.

How does LivaNova compare to Solventum?

LivaNova (NASDAQ:LIVN) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

LivaNova has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Solventum has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

In the previous week, Solventum had 7 more articles in the media than LivaNova. MarketBeat recorded 11 mentions for Solventum and 4 mentions for LivaNova. LivaNova's average media sentiment score of 1.25 beat Solventum's score of 0.37 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.6% of LivaNova shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 0.2% of Solventum shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Solventum has a net margin of 17.33% compared to LivaNova's net margin of 7.48%. Solventum's return on equity of 23.51% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Solventum	17.33%	23.51%	7.63%

LivaNova presently has a consensus price target of $77.22, suggesting a potential upside of 10.32%. Solventum has a consensus price target of $84.25, suggesting a potential upside of 13.46%. Given Solventum's higher possible upside, analysts clearly believe Solventum is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Solventum has higher revenue and earnings than LivaNova. Solventum is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.77	-$242.47M	$1.95	35.90
Solventum	$8.33B	1.54	$1.56B	$8.16	9.10

Summary

Solventum beats LivaNova on 9 of the 16 factors compared between the two stocks.

How does LivaNova compare to Penumbra?

LivaNova (NASDAQ:LIVN) and Penumbra (NYSE:PEN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Penumbra has a net margin of 11.76% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Penumbra	11.76%	10.87%	8.45%

LivaNova currently has a consensus price target of $77.22, suggesting a potential upside of 10.32%. Penumbra has a consensus price target of $361.33, suggesting a potential upside of 12.13%. Given Penumbra's higher possible upside, analysts plainly believe Penumbra is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

In the previous week, LivaNova and LivaNova both had 4 articles in the media. LivaNova's average media sentiment score of 1.25 beat Penumbra's score of 0.50 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.77	-$242.47M	$1.95	35.90
Penumbra	$1.45B	8.72	$177.69M	$4.34	74.25

97.6% of LivaNova shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

LivaNova has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Summary

Penumbra beats LivaNova on 9 of the 15 factors compared between the two stocks.

How does LivaNova compare to Glaukos?

LivaNova (NASDAQ:LIVN) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

97.6% of LivaNova shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 5.8% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

LivaNova currently has a consensus price target of $77.22, suggesting a potential upside of 10.32%. Glaukos has a consensus price target of $144.42, suggesting a potential upside of 0.62%. Given LivaNova's higher possible upside, equities analysts plainly believe LivaNova is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Glaukos has lower revenue, but higher earnings than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.77	-$242.47M	$1.95	35.90
Glaukos	$551.35M	15.29	-$187.69M	-$3.28	N/A

In the previous week, LivaNova had 1 more articles in the media than Glaukos. MarketBeat recorded 4 mentions for LivaNova and 3 mentions for Glaukos. LivaNova's average media sentiment score of 1.25 beat Glaukos' score of 0.29 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LivaNova has a net margin of 7.48% compared to Glaukos' net margin of -34.34%. LivaNova's return on equity of 16.48% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Glaukos	-34.34%	-6.92%	-5.25%

LivaNova has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Summary

LivaNova beats Glaukos on 9 of the 17 factors compared between the two stocks.

How does LivaNova compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

LivaNova has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.12	-$360M	-$0.62	N/A
LivaNova	$1.39B	2.77	-$242.47M	$1.95	35.90

In the previous week, Bausch + Lomb had 1 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Bausch + Lomb and 4 mentions for LivaNova. LivaNova's average media sentiment score of 1.25 beat Bausch + Lomb's score of 0.13 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch + Lomb presently has a consensus target price of $18.08, indicating a potential upside of 12.41%. LivaNova has a consensus target price of $77.22, indicating a potential upside of 10.32%. Given Bausch + Lomb's higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
LivaNova	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

Bausch + Lomb has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

LivaNova has a net margin of 7.48% compared to Bausch + Lomb's net margin of -4.21%. LivaNova's return on equity of 16.48% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
LivaNova	7.48%	16.48%	7.59%

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

LivaNova beats Bausch + Lomb on 12 of the 16 factors compared between the two stocks.

Get LivaNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIVN vs. The Competition

Export

Metric	LivaNova	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.94B	$6.75B	$6.43B	$12.48B
Dividend Yield	N/A	1.75%	2.80%	5.25%
P/E Ratio	35.90	49.11	20.38	25.24
Price / Sales	2.77	80.07	566.19	82.47
Price / Cash	14.82	24.21	43.04	56.04
Price / Book	3.17	6.49	9.87	6.90
Net Income	-$242.47M	$158.34M	$3.57B	$334.66M
7 Day Performance	-2.59%	-2.95%	0.31%	0.13%
1 Month Performance	7.68%	-4.36%	-1.27%	1.11%
1 Year Performance	57.66%	-4.45%	33.54%	30.62%

LivaNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIVN LivaNova	2.7766 of 5 stars	$70.00 -2.3%	$77.22 +10.3%	+59.7%	$3.94B	$1.39B	35.90	3,300	Positive News
SNN Smith & Nephew SNATS	2.2748 of 5 stars	$29.12 -2.8%	$30.93 +6.2%	+2.9%	$12.79B	$6.16B	N/A	16,988
SOLV Solventum	3.0936 of 5 stars	$74.12 +1.0%	$85.91 +15.9%	+1.8%	$12.71B	$8.33B	9.08	20,000	Analyst Downgrade
PEN Penumbra	3.2638 of 5 stars	$321.64 -0.2%	$361.33 +12.3%	+16.8%	$12.67B	$1.40B	74.11	4,700
GKOS Glaukos	2.2478 of 5 stars	$135.17 +1.2%	$144.42 +6.8%	+56.6%	$7.84B	$507.44M	N/A	1,094	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIVN) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LivaNova (LIVN) Competitors

LIVN vs. SNN, SOLV, PEN, GKOS, and BLCO

How does LivaNova compare to Smith & Nephew SNATS?

Summary

How does LivaNova compare to Solventum?

Summary

How does LivaNova compare to Penumbra?

Summary

How does LivaNova compare to Glaukos?

Summary

How does LivaNova compare to Bausch + Lomb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LivaNova (LIVN) Competitors

LIVN vs. SNN, SOLV, PEN, GKOS, and BLCO

How does LivaNova compare to Smith & Nephew SNATS?

Which has more risk & volatility, LIVN or SNN?

Does the media prefer LIVN or SNN?

Do insiders and institutionals hold more shares of LIVN or SNN?

Is LIVN or SNN more profitable?

Do analysts recommend LIVN or SNN?

Which has preferable valuation and earnings, LIVN or SNN?

Summary

How does LivaNova compare to Solventum?

Which has more risk & volatility, LIVN or SOLV?

Does the media prefer LIVN or SOLV?

Do insiders and institutionals hold more shares of LIVN or SOLV?

Is LIVN or SOLV more profitable?

Do analysts recommend LIVN or SOLV?

Which has preferable valuation and earnings, LIVN or SOLV?

Summary

How does LivaNova compare to Penumbra?

Is LIVN or PEN more profitable?

Do analysts rate LIVN or PEN?

Does the media prefer LIVN or PEN?

Which has stronger valuation and earnings, LIVN or PEN?

Do insiders and institutionals hold more shares of LIVN or PEN?

Which has more volatility & risk, LIVN or PEN?

Summary

How does LivaNova compare to Glaukos?

Do insiders and institutionals hold more shares of LIVN or GKOS?

Do analysts rate LIVN or GKOS?

Which has stronger valuation and earnings, LIVN or GKOS?

Does the media prefer LIVN or GKOS?

Is LIVN or GKOS more profitable?

Which has more volatility & risk, LIVN or GKOS?

Summary

How does LivaNova compare to Bausch + Lomb?

Which has stronger earnings and valuation, BLCO or LIVN?

Does the media favor BLCO or LIVN?

Do analysts recommend BLCO or LIVN?

Which has more risk and volatility, BLCO or LIVN?

Is BLCO or LIVN more profitable?

Do institutionals and insiders have more ownership in BLCO or LIVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools